협심증 치료제 시장 : 부문별 예측(2025-2030년)

The Angina Pectoris Drugs Market was valued at USD 1.14 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 5.39%, to USD 1.65 billion by 2030.

The scope of angina pectoris drugs encompasses the treatment and management of symptoms associated with chest pain resulting from insufficient blood flow to the heart. This category includes medications like nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents, which are crucial for alleviating angina symptoms and preventing heart attacks. The necessity of these drugs is underscored by the global prevalence of cardiovascular diseases and the rising geriatric population, making them indispensable in chronic care management. Their applications extend beyond symptom relief; they're integral in improving patient quality of life and reducing the incidence of major cardiovascular events. Primary end-use markets include hospitals, clinics, and retail pharmacies, with expanding reach in developing regions due to increasing health infrastructure and awareness.

Market growth is predominantly influenced by advancements in drug development and personalized medicine, alongside increasing healthcare expenditures. Emerging opportunities lie in the development of novel therapeutics targeting specific pathways involved in coronary artery disease, driven by ongoing research and technological innovations in pharmaceuticals. An increasing focus on preventive care and lifestyle modifications presents further opportunities for market penetration. However, growth is tempered by stringent regulatory environments, high costs of novel drug development, and potential side effects leading to patient non-compliance.

Key challenges include the competition from generics due to patent expirations and the need to balance efficacy with affordability in low-income markets. Innovation can flourish in areas such as gene therapy, development of combination drugs, and leveraging artificial intelligence to better predict patient responses and optimize drug formulations. Understanding complex patient needs and investing in R&D can lead to breakthroughs. A proactive approach to market expansion through strategic partnerships and rural market penetration can enhance accessibility. The angina pectoris drugs market is dynamic, with significant potential for growth driven by clinical innovation, yet it requires navigating through regulatory and economic challenges to fully realize these prospects.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angina Pectoris Drugs Market

The Angina Pectoris Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
  • Augmentation of novel drug delivery systems
  • Government suppport in strengthening the prevention and control of cardiovascular disease
• Market Restraints
  • Concerns regarding side effects associated with certain drug classes
• Market Opportunities
  • Technological advancements towards personalized cardiovascular medicine
  • Proliferation in the number of drug approvals and clinical research
• Market Challenges
  • Dearth of skilled and experienced professionals

Porter's Five Forces: A Strategic Tool for Navigating the Angina Pectoris Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angina Pectoris Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angina Pectoris Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angina Pectoris Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angina Pectoris Drugs Market

A detailed market share analysis in the Angina Pectoris Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angina Pectoris Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angina Pectoris Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angina Pectoris Drugs Market

A strategic analysis of the Angina Pectoris Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Prinzmetal Angina, Stable Angina, and Unstable Angina.
• Based on Drugs, market is studied across Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Nitrates, and Statins.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Transdermal.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
    • 5.1.1.2. Augmentation of novel drug delivery systems
    • 5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding side effects associated with certain drug classes
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements towards personalized cardiovascular medicine
    • 5.1.3.2. Proliferation in the number of drug approvals and clinical research
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of skilled and experienced professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Angina Pectoris Drugs Market, by Type

• 6.1. Introduction
• 6.2. Prinzmetal Angina
• 6.3. Stable Angina
• 6.4. Unstable Angina

7. Angina Pectoris Drugs Market, by Drugs

• 7.1. Introduction
• 7.2. Anti-Ischemic Agents
• 7.3. Antihypertensive Agents
• 7.4. Antiplatelet Agents
• 7.5. Beta-Adrenergic Blocking Agents
• 7.6. Calcium Channel Blockers
• 7.7. Nitrates
• 7.8. Statins

8. Angina Pectoris Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Transdermal

9. Angina Pectoris Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Angina Pectoris Drugs Market, by End-Users

• 10.1. Introduction
• 10.2. Homecare
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Angina Pectoris Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Angina Pectoris Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Angina Pectoris Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alembic Pharmaceuticals Limited
• 2. Alkem Laboratories Ltd.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bausch Health Companies Inc.
• 6. Bayer AG
• 7. Centurion Remedies Private Limited
• 8. Dr. Reddy's Laboratories
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline PLC
• 12. Intas Pharmaceuticals Ltd.
• 13. Ipca Laboratories Ltd.
• 14. Lupin Ltd.
• 15. Macleods Pharmaceuticals Pvt Ltd.
• 16. Mankind Pharma
• 17. Merck & Co. Inc.
• 18. Novartis AG
• 19. Otsuka Pharmaceutical Co., Ltd.
• 20. Pfizer Inc.
• 21. Sanofi-Aventis Groupe S.A.
• 22. Sumitomo Corporation
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Teva Pharmaceutical Industries Ltd.
• 25. Torrent Pharmaceuticals Ltd.